Patent classifications
A61K47/6933
Process for preparing stealth nanoparticles
A process for the preparation of targeting nanoparticles of a poly(alkyl cyanoacrylate) homopolymer or copolymer, wherein said method comprises, in a single step, the anionic polymerisation of an oil-in-water miniemulsion as herein defined. The invention also relates to nanoparticles produced from said process and to their use in medicine.
METHODS FOR TREATING TUMORS
The invention relates to methods for treating tumors. In particular, the invention provides novel use of nanoparticles in combination with ionizing radiations for treating tumors, wherein the combined effect of nanoparticles induces senescence and/or cannibalism of the tumor cells.
Polymeric Methylprednisolone Conjugates and Uses Thereof
Disclosed herein are polymeric methylprednisolone conjugates and prodrugs as well as method of using the same. Disclosed herein are methods of treating a spinal cord injury in a subject comprising: systemically delivering a composition comprising a polymeric methylprednisolone conjugate to the subject. Disclosed herein are methods of enhancing neuroprotection in a subject after spinal cord injury comprising systemically delivering a composition comprising a polymeric methylprednisolone conjugate to the subject.
NANOPARTICLES COMPRISING PEPTIDES INCLUDING AN N-TERMINAL LINKER
The present invention provides nanoparticles comprising: (a) an amphiphilic polymer with a number average molecular weight (Mn) of 20,000 g/mol or less; and (b) a peptide that is covalently linked to the polymer, wherein the peptide comprises 8 to 50 amino acids, including an N-terminal linker sequence comprising at least one Arg amino acid residue and a sequence comprising an MHC binding sequence comprising a T cell receptor epitope.
The present invention further comprises compositions comprising respective nanoparticles and a liquid or lyophilized carrier as well as nanoparticles and compositions of the invention for use in inducing tolerance to a therapeutic compound (protein, viral vector, lipid vesicle), an allergen or to an autoantigen or for treating an allergy, an autoimmune disease, an exogenous antigen (transplantation antigens, drugs) or a food intolerance.
MODIFIED RELEASE FORMULATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES
A particulate, modified release barrier coated drug-cation exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. Methods of making and products containing this coated complex are described.
Modified release formulations containing drug-ion exchange resin complexes
An aqueous liquid suspension containing a coated drug-ion exchange resin complex comprising a core composed of an amphetamine complexed with a pharmaceutically acceptable ion-exchange resin and an uncoated amphetamine-ion exchange resin complex is provided. The coated amphetamine-ion exchange resin complex is in admixture with a polymer to form a matrix. Methods of making the coated complex and the liquid suspension are described.
ALTERING INFLAMMATORY STATES OF IMMUNE CELLS IN VIVO BY MODULATING CELLULAR ACTIVATION STATES
Systems and methods to modulate the activation state of immune cells in vivo are described. The systems and methods can be used to transform immunosuppressive macrophages that support cancer growth and metastasis into highly activated tumoricidal macrophages.
COMPOSITIONS AND METHODS FOR TARGETING CELLS
The present invention provides compositions and methods for targeting cells for therapeutic and/or diagnostic purposes, e.g., delivery of therapeutic and/or diagnostic agents to a cell. Nanoparticles and polymers functionalized with capture molecules, reporter molecules, and/or therapeutic agents are provided for the treatment or prevention of disease, including neurological diseases associated with neuroinflammation, and cancer.
DECREASED ADHESIVITY RECEPTOR-TARGETED NANOPARTICLES FOR Fn14-POSITIVE TUMORS
Metastatic triple negative breast cancer (TNBC) still carries a dismal prognosis with the current treatment paradigms. The effectiveness of drug treatment for many solid tumors such as TNBC is limited by tumor heterogeneity, lack of tumor specificity, off-target toxicities, and transient therapeutic action(s). Strategies that provide tumor-specific, sustained concentrations of drugs to the tumors and tumor receptor-specific binding, while reducing off-target effects are needed to ensure sufficient tumor cell uptake within the primary and metastatic tumor microenvironment. The decreased non-specific adhesivity, receptor-targeted nanoparticle formulations (DART nanoparticles) of the invention were assessed for clinical potential in directing biological agents to the cell surface receptor Fn14, which is expressed in many solid cancer types, including TNBC primary tumors and metastatic lesions. They are contemplated for use against solid tumors, particularly brain tumors such as glioblastoma and breast cancer, including metastatic breast cancer.
BORIC ACID-CONTAINING POLYVINYL ALCOHOL NANOPARTICLE AND PREPARATION METHOD THEREOF
Provided are a boric acid-containing polyvinyl alcohol nanoparticle and a preparation method thereof. The boric acid-containing polyvinyl alcohol nanoparticle includes a polyvinyl alcohol nanoparticle and a boric acid, wherein the boric acid is crosslinked to the polyvinyl alcohol nanoparticle by covalent bonds.